Sevim Turanli1. 1. Department of General Surgery, Ankara Oncology Education and Research Hospital, Demetevler, Ankara, Turkey. turanlisevim@hotmail.com
Abstract
BACKGROUND AND AIMS: To investigate whether isolated bone metastases at the time of diagnosis is a different entity than bone metastases after breast cancer surgery. PATIENTS AND METHODS: One hundred thirty-nine patients were examined between June 2004 and January 2007. These patients were classified into synchronous (group I) and metachronous groups (group II) depending on time to development of bone metastases. Patients and tumor characteristics, treatment, clinical progression, and survival were compared for each group. RESULTS: There were 44 patients in group I and 95 patients in group II. The median follow-up time was 36 months. The two groups showed similar results when patients, tumor characteristics, and clinical progression were compared. In the groups, the median time to progression was 14 vs 13 months (p = 0.70), and median overall survival was 47 vs 46 months (p = 0.96), respectively. CONCLUSION: Development time of bone metastasis has no effect on clinical progression, time to progression, and overall survival in breast cancer.
BACKGROUND AND AIMS: To investigate whether isolated bone metastases at the time of diagnosis is a different entity than bone metastases after breast cancer surgery. PATIENTS AND METHODS: One hundred thirty-nine patients were examined between June 2004 and January 2007. These patients were classified into synchronous (group I) and metachronous groups (group II) depending on time to development of bone metastases. Patients and tumor characteristics, treatment, clinical progression, and survival were compared for each group. RESULTS: There were 44 patients in group I and 95 patients in group II. The median follow-up time was 36 months. The two groups showed similar results when patients, tumor characteristics, and clinical progression were compared. In the groups, the median time to progression was 14 vs 13 months (p = 0.70), and median overall survival was 47 vs 46 months (p = 0.96), respectively. CONCLUSION: Development time of bone metastasis has no effect on clinical progression, time to progression, and overall survival in breast cancer.
Authors: Gildy V Babiera; Roshni Rao; Lei Feng; Funda Meric-Bernstam; Henry M Kuerer; S Eva Singletary; Kelly K Hunt; Merrick I Ross; Karin M Gwyn; Barry W Feig; Frederick C Ames; Gabriel N Hortobagyi Journal: Ann Surg Oncol Date: 2006-04-17 Impact factor: 5.344
Authors: Elisabetta Rapiti; Helena M Verkooijen; Georges Vlastos; Gerald Fioretta; Isabelle Neyroud-Caspar; André Pascal Sappino; Pierre O Chappuis; Christine Bouchardy Journal: J Clin Oncol Date: 2006-05-15 Impact factor: 44.544
Authors: Evangelos Briasoulis; Vasilis Karavasilis; Lida Kostadima; Michael Ignatiadis; George Fountzilas; Nicholas Pavlidis Journal: Cancer Date: 2004-10-01 Impact factor: 6.860
Authors: Sharon H Giordano; Aman U Buzdar; Terry L Smith; Shu-Wan Kau; Ying Yang; Gabriel N Hortobagyi Journal: Cancer Date: 2004-01-01 Impact factor: 6.860
Authors: Yao Xu; Haixiao Wu; Guijun Xu; Zhuming Yin; Xin Wang; Vladimir P Chekhonin; Karl Peltzer; Shu Li; Huiyang Li; Jin Zhang; Wenjuan Ma; Chao Zhang Journal: Breast J Date: 2022-01-31 Impact factor: 2.269
Authors: M H T Ettaieb; J C Duker; R A Feelders; E P M Corssmit; C W Menke-van der Houven van Oordt; H J L M Timmers; M N Kerstens; J W Wilmink; P M Zelissen; B Havekes; H R Haak Journal: Horm Cancer Date: 2016-07-15 Impact factor: 3.869